Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-02-02
2010-11-30
Pak, Michael (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07842470
ABSTRACT:
This application relates to methods of identifying pharmacoperone agents that can restore function to a misfolded protein, such as a misfolded protein that causes disease. Also disclosed are methods of using such pharmacoperone agents to treat a disease or disorder that results from the misfolded protein.
REFERENCES:
patent: 5900360 (1999-05-01), Welch et al.
patent: 6270954 (2001-08-01), Welch et al.
patent: 6274597 (2001-08-01), Fan et al.
patent: 6541195 (2003-04-01), Welch et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6774135 (2004-08-01), Fan et al.
patent: 2002/0035072 (2002-03-01), Fan et al.
patent: 2002/0198225 (2002-12-01), Fan et al.
patent: 2005/0130972 (2005-06-01), Fan et al.
patent: 2005/0137223 (2005-06-01), Fan et al.
patent: WO 03/038036 (2003-05-01), None
Brothers et al., “Human Loss-of-Function Gonadotropin-Releasing Hormone Receptor Mutants Retain Wild-Type Receptors in the Endoplasmic Reticulum: Molecular Basis of the Dominant-Negative Effect,”Mol. Endocrinol. 18:1787-1797 (2004).
Castro-Fernandez et al., “Beyond the Signal Sequence: Protein Routing in Health and Disease,”Endocr. Rev. 26:479-503 (2005).
Conn et al., “Protein Origami: Therapeutic Rescue of Misfolded Gene Products,”Mol. Interventions 2:308-316 (2002).
Janovick et al., “Rescue of Hypogonadotropic Hypogonadism-Causing and Manufactured GnRH Receptor Mutants by Specific Protein-Folding Template: Misrouted Proteins as a Novel Disease Etiology and Therapeutic Target,”J. Clin. Endocrinol. Metab. 87:3255-3262 (2002).
Janovick et al., “Structure-Activity Relations of Successful Pharmacologic Chaperones for Rescue of Naturally Occurring and Manufactured Mutants of the Gonadotropin-Releasing Hormone Receptor,”J. Pharmacol. Exp. Ther. 305:608-614 (2003).
Leanos-Miranda et al., “In Vitro Coexpression and Pharmacological Rescue of Mutant Gonadotropin-Releasing Hormone Receptors Causing Hypogonadotropic Hypogonadism in Humans Expressing Compound Heterozygous Alleles,”J. Clin. Endocrinol. Metab. 90:3001-3008 (2005).
Leanos-Miranda et al., “Dominant-Negative Action of Disease-Causing Gonadotropin-Releasing Hormone Receptor (GnRHR) Mutants: A Trait that Potentially Coevolved with Decreased Plasma Membrane Expression of GnRHR in Humans,”J. Clin. Endocrinol. Met. 88:3360-3367 (2003).
Morello et al., “Pharmacological Chaperones Rescue Cell-Surface Expression and Function of Misfolded V2 Vasopressin Receptor Mutants,”J. Clin. Invest. 105:887-895 (2000).
Ulloa-Aguirre et al., “Pharmacologic Rescue of Conformationally-Defective Proteins: Implications for the Treatment of Human Disease,”Traffic 5:821-837 (2004).
Welch et al., “Influence of Molecular and Chemical Chaperones on Protein Folding,”Cell Stress Chaperones 1:109-115 (1996).
Leaños-Miranda et al., “Receptor-Misrouting: an Unexpectedly Prevalent and Rescuable Etiology in GnRHR-Mediated Hypogonadotropic Hypogonadism,”J. Clin. Endocrinol. Metab. 87:4825-4828, 2002.
Klarquist & Sparkman, LLP
Oregon Health & Science University
Pak Michael
LandOfFree
Method for pharmacoperones correction of GnRHR mutant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for pharmacoperones correction of GnRHR mutant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for pharmacoperones correction of GnRHR mutant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194859